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Background: We investigated how one pharmacokinetic (PK) model differed in prediction of plasma (Cp) and effect-
site concentration (Ceff) using a reproducing simulation of target-controlled infusion (TCI) with another PK model of 
propofol.
Methods: Sixty female patients were randomly assigned to TCI using Marsh PK (Group M) and TCI using Schnider 
PK (Group S) targeting 6.0 μg/ml of Cp of propofol for induction of anesthesia, and loss of responsiveness (LOR) was 
evaluated. Total and separate cross-simulation were investigated using the 2 hr TCI data (Marsh TCI and Schnider 
TCI), and we investigated the reproduced predicted concentrations (MARSHSCH and SCHNIDERMAR) using the other 
model. The correlation of the difference with covariates, and the influence of the PK parameters on the difference of 
prediction were investigated. 
Results: Group M had a shorter time to LOR compared to Group S (P < 0.001), but Ceff at LOR was not different 
between groups. Reproduced simulations showed different time courses of Cp. MARSHSCH predicted a higher 
concentration during the early phase, whereas SCHNIDERMAR was maintained at a higher concentration. Volume 
and clearance of the central compartment were relevant to the difference of prediction, respectively. Body weight 
correlated well with differences in prediction between models (Rsqr = 0.9821, P < 0.001).
Conclusions: We compared two PK models to determine the different infusion behaviors during TCI, which resulted 
from the different parameter sets for each PK model. (Korean J Anesthesiol 2012; 62: 309-316)
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Introduction
Pharmacokinetic (PK) models of propofol have been used 
in target controlled infusion (TCI) for the rapid achievement 
and maintenance of a stable plasma concentration (Cp) 
within a clinically acceptable range of performance errors [1-
3]. However, each PK model has different parameter values, 
even though the parent drug is the same. Recent reports using 
a non-linear mixed effect model present complex parameter 
sets that are expressed with complex equations of covariates. 
Commercially available TCI devices and PK software programs 
have various PK models for one drug. Therefore, we have 
faced some difficulties in choosing the appropriate PK model 
for routine clinical settings. Furthermore, time courses of 
predicted Cp and effect-site concentration (Ceff) of propofol were 
different when the manual bolus and continuous infusion were 
simulated using different PK models. Likewise, the amounts of 
propofol administered for maintenance of a stable Cp were also 
different between the PK models [4]. Therefore, we compared 
the PK models of propofol to investigate different infusion 
patterns using the reproducing simulation of TCI data of one PK 
model using another PK model.
Materials and Methods
With approval of the Institutional Review Board and signed 
informed consent, a total of 60 female patients, American 
Society of Anesthesiologists physical status I, age 20-50 years, 
and scheduled for gynecologic surgery under general anesthesia 
were enrolled in this study. Exclusion criteria included body 
weight of over 150% of ideal body weight, medications for 
the central nervous system, patients with chronic pain, or 
neurological and endocrine disorders. Patients received 
glycopyrrolate 0.2 mg intravenously for premedication; however, 
no other sedatives were administrated before and during 
the period of this study. Electrocardiograph, pulse oximeter, 
noninvasive blood pressure monitor, and capnogram were 
applied. Heart rate and blood pressure were monitored and 
recorded every 30 s during the study and thereafter every 3 min. 
After pre-oxygenation, lidocaine 30 mg was given and propofol 
TCI was started.
Patients were randomfly assigned to one of two groups. 
The three compartment mammillary pharmacokinetic model 
of Marsh PK [5] and 1.21/min of Ke0 [6] were used for Group 
M, and the multiple covariate-adjusted model of Schnider et 
al. [7,8] was used for Group S. The PK parameters and their 
equations with covariates and the Ke0 are illustrated in Table 1. 
Propofol (1% Fresofol
Ⓡ, Fresenius Kabi, Graz, Austria) was 
administrated using a syringe pump (Graseby 3500, Sims 
Graseby Ltd., Herts, England) targeting at 6.0 μg/ml of Cp for 
induction of anesthesia. The syringe pump was controlled 
using pharmacokinetic/pharmacodynamic (PK/PD) software 
(STANPUMP
Ⓒ, written by Steven L. Shafer, Palo Alto, CA, USA) 
through RS232 serial communication. The propofol-filled 
syringe was connected to the 3-channel extension tube with a 
unidirectional valve preventing the back flow to the intravenous 
bag. In the case of any alarm triggered from the TCI device 
during the study, the patient was also excluded from the study. 
Assessment of loss of responsiveness
About the time the patients became drowsy, a blind 
investigator assessed the loss of responsiveness (LOR), asking 
them to open their eyes with mild prodding of their shoulder 
every 10 s. Any responses to these stimuli, such as opening their 
eyes, nodding their head, and any kind of behavior showing an 
attempt to respond, were defined as ‘responsiveness’ , and no 
response was defined as ‘LOR’ . We have chosen the 10-s interval 
because the interval for pump control update and data saving 
was set at 10 s. Time to LOR, the predicted Ceff and the amount 
of propofol infused until LOR were recorded. Interventions were 
terminated when subjects had shown LOR. During the study, 
patients received oxygen via a facemask. If oxygen saturation 
decreased below 95%, they were encouraged to breathe deeply 
if they responded to verbal commands, and if not, then manual 
breathing was supported using an anesthetic breathing circuit 
system with oxygen, while maintaining the end-tidal CO2 
partial pressure between 30 and 35 mmHg. After LOR, opioid 
or neuromuscular blocking agents were administered, and 
tracheal intubation was done according to scheduled surgery. 
Total cross-simulation of the predicted plasma and 
effect-site concentrations
After surgery, two kinds of TCI regimen were simulated 
Table 1. Pharmacokinetic/Pharmacodynamic Parameters and 
Associated Equations with Covariates for Target-Controlled Infusion 
of Propofol
Marsh PK Schnider PK
VC (L)
K10 (/min)
K12 (/min)
K13 (/min)
K21 (/min)
K31 (/min)
Ke0 (/min)
0.228 × weight
0.119
0.112
0.0419
0.055
0.0033
1.21*
4.27
Cl1/4.27
Cl2/4.27
0.1958
Cl2/V2
0.0035
0.456
V2: 18.9 - 0.391 × (age - 53), Cl1: 1.89 + 0.0456 × (weight - 77) - 
0.0681 × (lbm - 59) + 0.0264 × (height - 177), Cl2: 1.29 - 0.024 × (age 
- 53), Age: age in years, Weight: body weight in kilograms, Height: 
height in centimeters, Lbm (lean body mass) for women: 1.07 × weight 
- 148 × (weight / height)
2. *Ke0 from the study of Struys et al. [6].311 www.ekja.org
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for every patient. (1) Regimen I: Two hour TCI was virtually 
performed targeting 6.0 μg/ml of Cp. (2) Regimen II: TCI was 
provided targeting 6.0 μg/ml of Cp (0 min to 10 min), then 
decreased to 4.0 μg/ml (10 min to 2 hr). The cumulative 
amounts of propofol infused until 1, 5, 10, 30, 60, 90, and 120 
min were compared between models. Total cross-simulation 
was performed using the reproducing function of STANPUMP
Ⓒ; 
the TCI using Marsh PK (Marsh TCI) was analyzed using 
Schnider PK (MARSHSCH), and the TCI using Schnider PK 
(Schnider TCI) was analyzed using Marsh PK (SCHNIDERMAR). 
The analysis was performed using the command line arguments 
with a patient-specific external parameter PK/PD file (e.g. 
Stanpump kinetics marsh.kin rep patient1.dat). In addition, 
the reproduced Cp (Cp-rep) and Ceff (Ceff-rep) were saved on a 
hard disk. We also investigated the correlation between the 
patient’s covariates (age, body weight, height, and LBM) and 
the percentage differences after 2 hr infusion. The percentage 
difference was calculated as follows:
Percentage difference (%) = 100 × (Cp-rep - Cp-prior) / Cp-prior
Time courses of Cp-rep and Ceff-rep were evaluated with the prior 
target plasma (Cp-prior) and effect-site concentration (Ceff-prior). 
Peak deviation from the prior target, time to intercept the prior 
predicted concentration, and Cp-rep and Ceff-rep at 30 min and 2 hr 
were compared. 
Separate cross-simulation of the predicted plasma 
concentrations
Separate cross-simulation was performed in order to 
determine the effect of one PK parameter on the overall 
differences. We replaced only one PK parameter of one model 
with the corresponding value of the other PK model, and 
performed simulations with the infusion data that targeted 6.0 
μg/ml of Cp. Each simulation was separately investigated for six 
PK parameters (VC, V2, V3, Cl1, Cl2, and Cl3), and time courses 
of the percentage difference were evaluated. The percentage 
difference was calculated as follows: 
Percentage difference (%) = 100 × (Cp-rep - Cp-prior) / Cp-prior
Statistics
Comparisons of demographic and hemodynamic variables, 
observations of LOR, total propofol infused, differences of Cp-rep and 
Ceff-rep were performed with the Student t-test (SPSS
Ⓒ, version 
10.0.1, SPSS Inc.) at a P < 0.05 level of significance. Data were 
presented as mean ± SD, unless stated otherwise. Regression 
between the covariates and the discrepancy observed in the 
predicted concentrations were performed with linear regression 
(SigmaPlot
Ⓒ 2004 for Windows Version 9.0, Systat Software, Inc., 
USA).
Results
There were no significant differences in the demographic 
data and hemodynamic variables between groups (Table 2). 
Group M showed shorter time to LOR compared to Group S (P 
< 0.001). However, the amount of propofol infused until LOR did 
not differ significantly between the groups (Table 3 and Fig. 1). Ceff 
Table 2. Demographic and Hemodynamic Variables of the Patients 
in this Study
Group M
(n = 30)
Group S
(n = 30)
Age (yr)
Weight (kg)
Height (cm)
Body surface area (m
2)
Lean body mass (kg)
Maximum % decrease in MAP
Maximum % decrease in heart rate
35.7 ± 7.1
58.4 ± 7.8
162.5 ± 4.7
1.58 ± 0.09
43.1 ± 3.7
20.6 ± 7.5
15.2 ± 7.6
38.7 ± 6.8
58.5 ± 7.1
160.0 ± 4.6
1.58 ± 0.13
42.5 ± 3.1
22.8 ± 15.2
14.7 ± 14.1
Data are reported as mean ± SD. There were no significances in patient 
groups.
Table 3. Observations at Loss of Responsiveness (LOR) and Predicted 
Effect Site Concentrations before and after Cross-Simulation
Group M 
(n = 30)
Group S
(n = 30)
Median LOR (s)
Mean LOR (s)
Propofol infused until LOR (mg/kg)
Predicted effect site concentration
  (μg/ml)
    Before simulation
    After simulation
90
114.3 ± 73.7*
2.04 ± 0.4
4.6 ± 1.10
5.1 ± 1.22
†
240
230.3 ± 50.3
2.05 ± 0.3
4.8 ± 0.48
4.5 ± 0.61
Data are reported as mean ± SD. *P < 0.001 vs. Group S , 
†P = 0.009 
vs. Group S.
Fig. 1. Scatter plots and error bars show the time to loss of respon-
siveness during target-controlled infusion of propofol using the 
pharmacokinetic model of Marsh et al. (Group M) and Schnider et 
al. (Group S).312 www.ekja.org
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at LOR did not differ between groups, but after cross-simulation 
using the other PK/PD model, Ceff at LOR were significantly 
different between groups (P = 0.009) (Table 3).
Total cross-simulation
Regimen I
Marsh TCI infused more propofol than Schnider TCI until 
1, 5, and 10 min (P < 0.001); in particular, nearly twice the 
amount of propofol was infused during Marsh TCI (98.6 ± 11.9 
mg) compared to Schnider TCI (48.4 ± 1.3 mg) during the first 1 
min after the start of infusion. However, Marsh TCI infused less 
propofol until 60 min (P = 0.009), 90 min (P = 0.01), and 120 min 
(P < 0.001) compared to Schnider TCI (Fig. 2). 
MARSHSCH showed that Cp-rep was over-predicted up to 15.4 
± 1.86 μg/ml, and decreased to Cp-prior at 3.3 min after the start 
of infusion (Fig. 3, left upper graph). Thereafter, it gradually 
Fig. 2. Cumulative amounts of infused propofol targeting 6.0 μg/ml 
of plasma concentration during 2 hr of target controlled infusion 
with the pharmacokinetic (PK) model of Marsh (solid line) and 
Schnider et al. (dotted line). Error bars show the amount of propofol 
infused until 1, 5, 10, 60, 90, and 120 min. 
Fig. 3. The time courses of the reproduced individual (dotted line) and mean (black solid line) predicted plasma (upper graphs) and effect-site 
(lower graphs) concentrations of propofol targeting 6.0 μg/ml of plasma concentration (gray line). The infusion data file of the pharmacokinetic 
(PK) model of Marsh et al. (Marsh PK) was analyzed using that of Schnider et al. (Schnider PK) (left graphs), and the infusion data file of 
Schnider PK was analyzed using Marsh PK (right graphs).313 www.ekja.org
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decreased to 5.4 ± 0.44 μg/ml at 30 min (P < 0.001) and 5.1 ± 0.35 
μg/ml at 2 hr (P < 0.001). Ceff-rep was also over-predicted up to 
6.3 ± 0.71 μg/ml at 2.9 min (P < 0.001) (Fig. 3, left lower graph). 
Thereafter, it gradually decreased to 5.4 ± 0.45 μg/ml at 30 min (P < 
0.001) and 5.2 ± 0.35 μg/ml at 2 hr (P < 0.001). The percentage of 
difference of prediction at the end of the 2 hr infusion correlated 
well with body weight (Rsqr = 0.9821, P < 0.001) (Fig. 4), and LBM 
also correlated well (Rsqr = 0.9603, P < 0.001).
SCHNIDERMAR showed that Cp-rep was under-predicted 
during the initial period of infusion and while it reached Cp-prior 
at 7.5 min. It then increased to 6.61 ± 0.51 μg/ml at 30 min 
(P < 0.001) and 6.94 ± 0.45 μg/ml at 2 hr (P < 0.001). Ceff-rep 
increased more slowly than Ceff-prior during the early period of 
infusion and became Ceff-prior at 8.7 min. It then increased to 
6.61 ± 0.51 μg/ml at 30 min (P < 0.001) and 6.9 ± 0.45 μg/ml at 
2 hr (P < 0.001).
Fig. 4. Regression of the body weight with the percentage difference 
of predicted plasma concentrations after 2 hr of infusion targeting 6.0 
μg/ml of plasma concentration (Rsqr = 0.9821, P < 0.001). The infusion 
data file of the pharmacokinetic model of Marsh et al. was analyzed 
using that of Schnider. 
Fig. 5. Total cross-simulation shows the time courses of the reproduced individual (dotted line) and mean (black solid line) predicted plasma 
(upper graphs) and effect-site (lower graphs) concentrations of propofol. Targeting 6.0 μg/ml of plasma concentration (0 to 10 min), and 4.0 μg/
ml (10 min to 2 hr) (gray line). The infusion data file of the pharmacokinetic (PK) model of Marsh et al. (Marsh PK) was analyzed using the file of 
Schnider et al. (Schnider PK) (left graphs), and the infusion data file of Schnider PK was analyzed using Marsh PK (right graphs).314 www.ekja.org
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Regimen II
Patterns of discrepancy during the first 10 min were similar 
to those of Regimen I. After the target concentration decreased 
to 4 μg/ml, MARSHSCH showed that Cp-rep decreased to 2.0 ± 
0.13 μg/ml, and increased to 3.6 ± 0.28 μg/ml at 30 min (P < 
0.001), then decreased to 3.4 ± 0.23 μg/ml at the end of the 2 hr 
infusion (P < 0.001) (Fig. 5, left upper graph). After the target 
concentration decreased to 4 μg/ml, Ceff-rep decreased to 3.4 ± 
0.30 μg/ml at 14.3 min, and became 3.6 ± 0.29 μg/ml at 30 min (P 
< 0.001). It finally decreased to 3.4 ± 0.23 μg/ml at the end of the 
2 hr infusion (P < 0.001) (Fig. 4, left lower graph).
After the target decreased to 4 μg/ml, SCHNIDERMAR showed 
that Cp-rep decreased, but remained higher than Cp-prior and 
increased to 4.5 ± 0.36 μg/ml at 30 min (P < 0.001) and 4.7 ± 
0.34 μg/ml at 2 hr (P < 0.001) (Fig. 4, right upper graph). After 
the target concentration decreased to 4 μg/ml, Ceff-rep showed a 
much slower decrease, but remained higher than Ceff-prior, and 
showed a maximal decrease to 4.4 ± 0.35 μg/ml at 24.3 min, and 
increased to 4.4 ± 0.34 μg/ml at 30 min (P < 0.001) and 4.6 ± 0.29 
μg/ml at 2 hr (P < 0.001) (Fig. 4, right lower graph).
Separate cross-simulation
The mean ± SD or fixed values of PK parameters for separate 
cross-simulation are illustrated in Table 4. Fig. 6 shows the 
time course of the percentage difference of each parameter. VC 
appeared to be relevant to the initial large difference. Thereafter, 
Cl1 and V3 increasingly contributed to the difference until 2 hr 
of infusion. The upper and lower graphs show a mirror image, 
and the summation curve of the percentage differences of 
each parameter appeared to be similar with MARSHSCH and 
SCHNIDERMAR of Regimen I. 
Discussion
During TCI of propofol, the infusion data files that were 
supposed to maintain a stable Cp did not produce identical 
results when played back to a different PK model. The 
differences were greater during the early period of infusion, 
whereas later a relatively stable range of differences was 
maintained, but with a continual increase during long-term 
infusion. These discrepancies highly correlated with the body 
weight of the subject.
Using simulations, we attempted to perform a straightfor-
ward comparison of the integrated difference of the two PK 
models. Apparently, the volume of the central compartment 
of Marsh PK was nearly triple that of Schnider PK. Therefore, 
Marsh PK required a larger amount of propofol to fill up the 
central compartment when there was no drug in the body, 
and, as a result, showed a more rapid loss of responsiveness 
Fig. 6. Simulation was separately investigated with one pharmaco-
kinetic (PK) parameter (VC, V2, V3, Cl1, Cl2, and Cl3) replaced of the 
PK model with the corresponding value of the other model and 
each curve shows the time course of the percentage differences of 
predictions. Each parameter of Marsh PK was replaced with that of 
Schnider PK (upper curves), and each parameter of Schider PK was 
replaced with that of Marsh PK (lower curves).
Table 4. Values for Pharmacokinetic Parameters of Propofol
Marsh PK
(n = 60)
Schnider PK
(n = 60)
VC (L)
V2 (L)
V3 (L)
Cl1 (L/min)
Cl2 (L/min)
Cl3 (L/min)
K10 (/min)
K12 (/min)
K13 (/min)
K21 (/min)
K31 (/min)
13.35 ± 1.70
27.2 ± 3.47
169.6 ± 21.63
1.59 ± 0.202
1.50 ± 0.190
0.5596 ± 0.0714
0.1190
0.1120
0.0419
0.0550
0.0033
4.27
25.1 ± 2.77
238.9
1.73 ± 0.164
1.67 ± 0.170
0.8361
0.4044 ± 0.0384
0.3907 ± 0.0398
0.1958
0.0666 ± 0.0006
0.0035
Data are reported as mean ± SD or fixed values.315 www.ekja.org
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Fig. 7. Clearances of the central com-
part  ment of Marsh PK (gray mesh, left 
graph) and Schnider PK (transparent 
mesh, right graph), and the difference 
of the clearances between the models 
of propofol (lower graph) according to 
patient body weight and height.
than Schnider PK. However, the clearance of the central com-
partment of Marsh PK was smaller than that of Schnider PK. 
Therefore; we could deduce that Marsh TCI requires less 
propofol than Schnider TCI. These differences appeared to be 
distinct when we simply compared the cumulative amounts of 
propofol and the PK parameters (3 volumes and 3 clearances). 
However, the degree of discrepancy during TCI and time course 
of the predicted concentration could not be determined. 
Therefore, we performed total and separate cross-simulation. 
During the early phase of infusion, the difference of Cp was 
significant. Thereafter, overall differences were shown to be 
roughly 10% (at 30 min) and 15% (at 2 hr) under- or over-
prediction of Cp, and the differences showed a gradual increase 
with time. However, total cross-simulations could not explain 
the impact of each parameter on the overall difference of 
prediction. Therefore, we performed separate cross-simulations. 
Young and Shafer [9] also demonstrated the changes of Cp and 
decrement time of three opioids by independently changing the 
volumes and clearance of the three compartments. They used 
simulations that were similar to our method, while predicting 
the change in Cp of opioid after a bolus if each pharmacokinetic 
parameter were independently increased by 5%. Our separate 
cross-simulation showed that VC mainly contributed to the 
initial differences, and Cl1 and V3 to the difference of long-term 
infusion. The difference of Cl3 also seemed to be an important 
factor during the initial period, but contributed less during long 
term infusion. 
Even though Marsh TCI showed a more rapid loss of 
responsiveness than Schnider TCI, the amount of propofol 
infused until LOR and Ceff at LOR did not differ between the 
groups (Table 3). The ke0 used for Marsh PK was 1.21/min [6], 
whereas 0.456/min was used for Schnider PK. The volume of 
distribution of Schnider PK was small and time to LOR was long 
during Schnider TCI, but the predicted Ceff slowly increased 
because of its smaller ke0 than Marsh PK. Therefore, Ceff at 
LOR appeared to be insignificant between groups. However, 
the reproduced Ceff at LOR after simulation was significantly 
different between groups. During TCI, Ceff is calculated using 
the ke0 and Cp. However, the value of ke0 is highly influenced by 
the PK model and it was reported that it is unwise to use the 
ke0 from one PK model with another PK model from a different 
study [6,10,11]. 
Body weight and LBM correlated well with the discrepancies 
of prediction. LBM is calculated using body weight and height. 
In Marsh PK, body weight influences VC, V2, V3, Cl1, Cl2, and 
Cl3. As a result, decreasing body weight leads to a smaller 
volume and clearance of each compartment. In addition, the 
relationship between Cl1 and height-body weight showed a flat 
mesh (Fig. 7, left graph, gray mesh). In Schnider PK, only Cl1 is 
influenced by body weight and height. Decreasing body weight 
and height leads to smaller Cl1, and increasing height with lower 
body weight or decreasing height with higher body weight leads 
to a higher Cl1 (Fig. 7, left graph, transparent mesh). Therefore, 
a taller patient with a lower body weight or a shorter obese 
patient showed a larger difference of clearance between the two 
models (Fig. 7, Right graph). Accordingly, there could be a large 
difference in the level of hypnosis between models during the 
TCI to these types of patients.
In our study, the mean Cl1 of Schnider PK was 8.8% higher 
than that of Marsh PK. Wietasch et al. reported that they found 
a smaller VC (3.55 L) than Marsh PK, and Cl1 was reduced to 
1.31 L/min in comparison with that of Marsh PK (2.04 L/min) 
and Schnider PK (1.89 L/min) [3]. In this study, contrary to 
our study, Cl1 of Marsh PK was greater than Schnider PK, and 
mean body weights of subjects were around 75 kg, which was 
the heaviest body weight in our study. Kim et al. [12] reported 
that the VC of lipid emulsion of propofol was 3.9 L and Cl1 was 
1.53 L/min. Jung et al. [13] reported that VC of lipid emulsion of 
propofol was 6.78 L and Cl1 was 1.46 L/min. The populations 
of these two reports were similar overall to those of our study. 
Marsh PK and Schnider PK are known to under-predict Cp [3,14]. 
White et al. [15] also suggested the use of the parameters of 316 www.ekja.org
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Marsh PK adjusted with the covariates, such as age and gender. 
Therefore, the possibility of overdose of propofol using Schnider 
PK could increase during long term infusion, especially for 
patients with low body weight.
There are some caveats that need to be taken into conside-
ration. First, our study evaluated the PD difference between the 
models, only for the period of induction of anesthesia. Further 
study on the PD differences during maintenance of anesthesia 
and recovery period will be helpful in differentiation of the 
characteristics between the models. Second, the population 
of this study was limited to females. TCI using Marsh PK 
administers propofol irrelevant to gender. However, Schnider 
PK estimates different Cl1 according to gender. The covariate, 
LBM, used for calculation of Cl1, is differently calculated 
according to gender; men, LBM = 1.1 × weight - 128 × (weight /
height)
2; women, LBM = 1.07 × weight - 148 × (weight / height)
2 
[16]. Cl1 for women is calculated higher than that of men when 
other covariates are equal. Therefore, the results of this study 
could be different if investigated for both genders. Third, it took 
nearly 4 min to induce LOR using Schnider PK. The longest 
time to LOR was 310 s in Group S, which is considered to be 
inadequate for the routine induction of anesthesia. Therefore, 
other modalities, such as higher target of Cp or targeting Ceff, are 
indicated.
The primary goal of this study was to increase our under-
standing between the different PK models and the influence 
of PK parameters on the infusion patterns during TCI. This 
comparison method between PK models would be helpful 
in selection of an appropriate PK model of a certain drug in 
clinical settings and research fields.
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